Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria

Journal of Chemotherapy

Volumn 15, Issue 2, 2003, Pages 113-117

  Phillips, O A ^a   Rotimi, V O ^a   Jamal, W Y ^a   Shahin, M ^a   Verghese, T L ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Clostridium difficile; Linezolid; Other anaerobes; Oxazolidinone; PH 027; Susceptibility testing

Indexed keywords

5 TRIAZOLOXAZOLIDINONE; ANTIBIOTIC AGENT; LINEZOLID; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PH 027; PIPERACILLIN; TAZOBACTAM; TEICOPLANIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DILUTION; FUSOBACTERIUM; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PREVOTELLA BIVIA;

EID: 0037951783     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.2.113     Document Type: Article

References (18)

1. Rotimi VO, Khoursheed M, Brazier JS, Jamal WY. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin Microbiol Infect 1999; 5: 166-169.
2. Ueno K, Watanabe K, Bando K, Kato N. The antimicrobial susceptibility of recent clinical isolates of Bacteroides fragilis group. Clin Infect Dis 1993; 6 (Suppl 4): 382-386.
3. Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC: Susceptibility of 497 clinical isolates of Gram-negative anaerobes to trovafloxacin and eight other antibiotics. J Chemother 1999; 11: 349-356.
4. th Interscience Conference on Antimicrobial Agents Chemotherapy, American Society for Microbiology, Washington, D.C. 1998. Abstr. E-173, p.219.
5. Watanabe K, Ueno K, Kato N, et al. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan. Eur J Clin Microbiol Infect Dis 1992; 11: 1069-1073.
6. Jacobs MR, Spangler SK, Appelbaum PC. Beta-lactamase production and susceptibility of US and European anaerobic Gram-negative bacilli to beta-lactam and other agents. Eur J Clin Microbiol Infect Dis 1992; 11: 1081-1093.
7. Perry CM, Jarvis B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525-51.
8. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, Denbesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357 (9263): 1179.
9. Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid. Clin Infect Dis 2000; 31 (Suppl 4): 144-149.
10. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001; 85 (1): 1-17.
11. Peláez T, Alonso R, Pérez C, Alcalá L, Cuevas O, Bouza E. In vitro activity of linezolid against Clostridium difficile. Antimicrob Agents Chemother 2002; 46: 1617-1618.
12. Edlund C, Oh O, Nord C. In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin Microbiol Infect 1999; 5: 51-53.
13. Phillips OA, Udo EE, Ali AAM, Al-Hassawi N. Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem 2003; 11 (1): 5-11.
14. th edition, Star Publishing Company, 1993.
15. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial susceptibility testing for anaerobic bacteria, Approved standard M11-A4, Vol 17, No.22, Villanova; NCCLS, 1997.
16. Finegold SM. Overview of clinically important anaerobes. Clin Infect Dis 1995; 20 (Suppl 2): 205-207.
17. Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 1990; 12 (Suppl 2): 243-251.
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283-284.